And being 'a bit under pressure' (as rest of Big Pharma) not the least US - in the Novo Stock is now again at an ATH - so 'things back to normal' at Novo Nordisk.
The center of the Novo succes is Diabetes. Maybe not Novo right now as possible BO - but Novo would be a great Partner in getting EU of the ramp - and maybe 'some combination possibilities' in the Diabetes - Vascepa - treatment - actually curing people.
Better Novo do it themselves (a lot of other efforts to attack Diabetes problematic especially in USA - with the obvious big obesity problem).